As a neurological disease with high morbidity, mortality and disability, ischemic stroke poses a serious threat to human health, and effective preventive measures can largely delay its occurrence and development. Astragaloside, as the main active ingredient of Astragalus, has a variety of immunomodulatory effects including anti-oxidative stress and anti-inflammation. However, there is no summary report on the pharmacodynamic mechanism of astragaloside on the pre-pathogenesis of stroke. Several studies have shown that AS-IV can improve coagulation function, smooth muscle cells, and vascular dysfunction. Therefore, this review focuses on the mechanism of action and constitutive relationship of astragaloside on ischemic stroke mainly based on the perspective of pre-protection prior to the occurrence of cerebral ischemia, aiming to summarize the progress of the research on astragaloside in the pre-pathogenesis of stroke and to explore the direction of its potential application.

Jiapeng Yao, Danni Li, Zhangwei Chen.Current Research Progress on the Preprotection of Astragaloside on Ischemic Stroke and Its Mechanism. International Journal of Frontiers in Medicine(2025), Vol. 7, Issue 2: 35-40. https://doi.org/10.25236/IJFM.2025.070206.

[1] Shakir, R. The struggle for stroke reclassification. Nat Rev Neurol 14, 447–448 (2018).

[2] GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet S0140-6736(24)00367–2 (2024) doi: 10.1016/S0140-6736(24)00367-2.

[3] Ma, Q. et al. Temporal trend and attributable risk factors of stroke burden in China, 1990-2019: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 6, e897–e906 (2021).

[4] Wang, Y.-J. et al. China Stroke Statistics: an update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases. Stroke Vasc Neurol 7, 415–450 (2022).

[5] Zhu, T., Wang, L., Wang, L.-P. & Wan, Q. Therapeutic targets of neuroprotection and neurorestoration in ischemic stroke: Applications for natural compounds from medicinal herbs. Biomed Pharmacother 148, 112719 (2022).

[6] Dehghan, M. et al. Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries. Circulation 126, 2705–2712 (2012).

[7] Landau, W. M., Willey, J. Z. & Elkind, M. S. V. Physical activity and risk of ischemic stroke in the Northern Manhattan study. Neurology 75, 94; author reply 94 (2010).

[8] Diener, H.-C. & Hankey, G. J. Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar. J Am Coll Cardiol 75, 1804–1818 (2020).

[9] Advanced drug delivery system against ischemic stroke - PubMed. https://pubmed.ncbi.nlm.nih.gov/35248645/.

[10] Liu, L. et al. Traditional Chinese medicine in treating ischemic stroke by modulating mitochondria: A comprehensive overview of experimental studies. Front Pharmacol 14, 1138128 (2023).

[11] Li, L., Hou, X., Xu, R., Liu, C. & Tu, M. Research review on the pharmacological effects of astragaloside IV. Fundam Clin Pharmacol 31, 17–36 (2017).

[12] Rao, Α. V. & Gurfinkel, D. M. The Bioactivity of Saponins: Triterpenoid and Steroidal Glycosides. Drug Metabolism and Drug Interactions 17, (2000).

[13] Costa, I. M. et al. Astragaloside IV Supplementation Promotes A Neuroprotective Effect in Experimental Models of Neurological Disorders: A Systematic Review. CN 17, 648–665 (2019).

[14] Zhang, W.-J., Wojta, J. & Binder, B. R. Regulation of the Fibrinolytic Potential of Cultured Human Umbilical Vein Endothelial Cells: Astragaloside IV Downregulates Plasminogen Activator Inhibitor-1 and Upregulates Tissue-Type Plasminogen Activator Expression. J Vasc Res 34, 273–280 (1997).

[15] Sheng, S. et al. Network pharmacology analyses of the antithrombotic pharmacological mechanism of Fufang Xueshuantong Capsule with experimental support using disseminated intravascular coagulation rats. Journal of Ethnopharmacology 154, 735–744 (2014).

[16] Dang, X. et al. The antithrombotic effect of RSNK in blood-stasis model rats. Journal of Ethnopharmacology 173, 266–272 (2015).

[17] Sun, H. et al. Fufang Xueshuantong alleviates diabetic retinopathy by activating the PPAR signalling pathway and complement and coagulation cascades. Journal of Ethnopharmacology 265, 113324 (2021).

[18] Chen, Z., Cai, Y., Zhang, W., Liu, X. & Liu, S. Astragaloside IV inhibits platelet-derived growth factor-BB-stimulated proliferation and migration of vascular smooth muscle cells via the inhibition of p38 MAPK signaling. Experimental and Therapeutic Medicine 8, 1253–1258 (2014).

[19] Yuan, W. et al. Astragaloside IV Inhibits Proliferation and Promotes Apoptosis in Rat Vascular Smooth Muscle Cells under High Glucose Concentration in vitro. Planta Med 74, 1259–1264 (2008).

[20] Yuan W. The protective effect of astragaloside on vascular remodeling in diabetes mellitus and its related mechanisms. (Zhejiang University, 2009).

[21] Lu, Y. et al. Beneficial effects of astragaloside IV against angiotensin II-induced mitochondrial dysfunction in rat vascular smooth muscle cells. International Journal of Molecular Medicine 36, 1223–1232 (2015).

[22] Dikalov, S. I. & Nazarewicz, R. R. Angiotensin II-Induced Production of Mitochondrial Reactive Oxygen Species: Potential Mechanisms and Relevance for Cardiovascular Disease. Antioxidants & Redox Signaling 19, 1085–1094 (2013).

[23] Li, H.-B., Ge, Y.-K., Zhang, L. & Zheng, X.-X. Astragaloside IV improved barrier dysfunction induced by acute high glucose in human umbilical vein endothelial cells. Life Sciences 79, 1186–1193 (2006).

[24] Zhang, C. et al. MECHANISMS UNDERLYING VASORELAXANT ACTION OF ASTRAGALOSIDE IV IN ISOLATED RAT AORTIC RINGS. Clin Exp Pharmacol Physiol 34, 387–392 (2007).

[25] Qiu, L.-H., Xie, X.-J. & Zhang, B.-Q. Astragaloside IV Improves Homocysteine-Induced Acute Phase Endothelial Dysfunction via Antioxidation. Biological & Pharmaceutical Bulletin 33, 641–646 (2010).

[26] Xu, C. et al. Astragaloside IV improves the isoproterenol-induced vascular dysfunction via attenuating eNOS uncoupling-mediated oxidative stress and inhibiting ROS-NF-κB pathways. International Immunopharmacology 33, 119–127 (2016).

[27] Nie, Q., Zhu, L., Zhang, L., Leng, B. & Wang, H. Astragaloside IV protects against hyperglycemia-induced vascular endothelial dysfunction by inhibiting oxidative stress and Calpain-1 activation. Life Sciences 232, 116662 (2019).

[28] Zhang, W.-D. et al. Astragaloside IV Dilates Aortic Vessels from Normal and Spontaneously Hypertensive Rats through Endothelium-Dependent and Endothelium-Independent Ways. Planta med 72, 621–626 (2006). 

[29] Zhang, N., Wang, X.-H., Mao, S.-L. & Zhao, F. Astragaloside IV Improves Metabolic Syndrome and Endothelium Dysfunction in Fructose-Fed Rats. Molecules 16, 3896–3907 (2011).

[30] Chen, B. et al. Inhibition of calpain reduces oxidative stress and attenuates endothelial dysfunction in diabetes. Cardiovasc Diabetol 13, 88 (2014).